Macrogenics PE ratio MGNX

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 23.8×; Mar 2024
Peer median: 11.3×

Macrogenics has no meaningful PE ratio today: it lost $0.22 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Mar 2024, at 23.8×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	23.8×	12.2×	23.8×
2023	12.0×	8.0×	49.4×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	235×	182×	243×

Against its peers

Companies in Drug Manufacturers - General nearest Macrogenics' size, closest first, today.

Company	PE ratio
MGNXMacrogenics	n/m
NATRNatures Sunshine Products	12.0×
LFVNLifevantage	14.7×
SPROSpero Therapeutics	10.1×
ATNMActinium Pharmaceuticals	4.2×
ARVNArvinas	45.6×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
Peer median	11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Macrogenics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.